ALK and uterine corpus sarcoma: We also reported TNS1-ALK fusions in two uterine sarcomas, and a case report described a patient with leiomyosarcoma benefiting from matched therapy with the ALK inhibitor brigatinib after failing multiple lines of chemotherapy [71].